REMeDio: a proof-of-concept neuroprotection study for prodromal synucleinopathies.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of neurology"
DOI: 10.1111/ene.14664
Abstract: OBJECTIVE To explore the feasibility of a neuroprotection trial in prodromal synucleinopathy, using idiopathic REM sleep behavior disorder (iRBD) as the target population and 123 I-FP-CIT-SPECT as a biomarker of disease progression. METHODS Consecutive iRBD… read more here.
Keywords: treatment; cit spect; arm; 123 cit ... See more keywords
Serial changes of I-123 FP-CIT SPECT binding asymmetry in Parkinson's disease: Analysis of the PPMI data
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Neurology"
DOI: 10.3389/fneur.2022.976101
Abstract: Background Dopaminergic denervation and motor symptoms are usually asymmetric at the onset of Parkinson's disease (PD). In this study, we estimated the asymmetry of specific binding ratio (SBR) of I-123 FP-CIT SPECT images during 4-years… read more here.
Keywords: 123 cit; asymmetry index; asymmetry; cit spect ... See more keywords